Research ExplorerPublicationsPreferences of German and Swiss melanoma patients for toxici...

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

Standard

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial). / Kähler, Katharina C; Hüning, S; Nashan, D; Meiss, F; Rafei-Shamsabadi, D A; Rissmann, H; Colapietro, C; Livingstone, E; Maul, L V; Heppt, M; Hassel, J C; Gutzmer, R; Loquai, C; Heinzerling, L; Sachse, M M; Bohne, A S; Moysig, L; Peters, W; Rusch, J; Blome, C.

In: J CANCER RES CLIN, Vol. 149, No. 13, 10.2023, p. 11705-11718.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kähler, KC, Hüning, S, Nashan, D, Meiss, F, Rafei-Shamsabadi, DA, Rissmann, H, Colapietro, C, Livingstone, E, Maul, LV, Heppt, M, Hassel, JC, Gutzmer, R, Loquai, C, Heinzerling, L, Sachse, MM, Bohne, AS, Moysig, L, Peters, W, Rusch, J & Blome, C 2023, 'Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)', J CANCER RES CLIN, vol. 149, no. 13, pp. 11705-11718. https://doi.org/10.1007/s00432-023-05027-z

APA

Kähler, K. C., Hüning, S., Nashan, D., Meiss, F., Rafei-Shamsabadi, D. A., Rissmann, H., Colapietro, C., Livingstone, E., Maul, L. V., Heppt, M., Hassel, J. C., Gutzmer, R., Loquai, C., Heinzerling, L., Sachse, M. M., Bohne, A. S., Moysig, L., Peters, W., Rusch, J., & Blome, C. (2023). Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial). J CANCER RES CLIN, 149(13), 11705-11718. https://doi.org/10.1007/s00432-023-05027-z

Vancouver

Kähler KC, Hüning S, Nashan D, Meiss F, Rafei-Shamsabadi DA, Rissmann H et al. Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial). J CANCER RES CLIN. 2023 Oct;149(13):11705-11718. https://doi.org/10.1007/s00432-023-05027-z

Bibtex

@article{6c9dddaa958f4346ad1e40e270cfe2b0,
title = "Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)",
abstract = "PURPOSE: Adjuvant treatment with immune checkpoint inhibitors like PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT) in high-risk melanoma patients demonstrate a significant improvement in disease-free survival (DFS). Due to specific side effects, the choice of treatment is very often driven by the risk for toxicity. This study addressed for the first time in a multicenter setting the attitudes and preferences of melanoma patients for adjuvant treatment with (c)ICI and TT.METHODS: In this study ({"}GERMELATOX-A{"}), 136 low-risk melanoma patients from 11 skin cancer centers were asked to rate side effect scenarios typical for each (c)ICI and TT with mild-to-moderate or severe toxicity and melanoma recurrence leading to cancer death. We asked patients about the reduction in melanoma relapse and the survival increase at 5 years they would require to tolerate defined side-effects.RESULTS: By VAS, patients on average valued melanoma relapse worse than all scenarios of side-effects during treatment with (c)ICI or TT. In case of severe side effects, patients required a 15% higher rate of DFS at 5 years for (c)ICI (80%) compared to TT (65%). For survival, patients required an increase of 5-10% for melanoma survival during (c)ICI (85%/80%) compared to TT (75%).CONCLUSION: Our study demonstrated a pronounced variation of patient preferences for toxicity and outcomes and a clear preference for TT. As adjuvant melanoma treatment with (c)ICI and TT will be increasingly implemented in earlier stages, precise knowledge of the patient perspective can be helpful for decision making.",
keywords = "Humans, Switzerland/epidemiology, Neoplasm Recurrence, Local/drug therapy, Melanoma/therapy, Skin Neoplasms, Skin, Protein Kinase Inhibitors/therapeutic use, Retrospective Studies",
author = "K{\"a}hler, {Katharina C} and S H{\"u}ning and D Nashan and F Meiss and Rafei-Shamsabadi, {D A} and H Rissmann and C Colapietro and E Livingstone and Maul, {L V} and M Heppt and Hassel, {J C} and R Gutzmer and C Loquai and L Heinzerling and Sachse, {M M} and Bohne, {A S} and L Moysig and W Peters and J Rusch and C Blome",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = oct,
doi = "10.1007/s00432-023-05027-z",
language = "English",
volume = "149",
pages = "11705--11718",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "13",

}

RIS

TY - JOUR

T1 - Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

AU - Kähler, Katharina C

AU - Hüning, S

AU - Nashan, D

AU - Meiss, F

AU - Rafei-Shamsabadi, D A

AU - Rissmann, H

AU - Colapietro, C

AU - Livingstone, E

AU - Maul, L V

AU - Heppt, M

AU - Hassel, J C

AU - Gutzmer, R

AU - Loquai, C

AU - Heinzerling, L

AU - Sachse, M M

AU - Bohne, A S

AU - Moysig, L

AU - Peters, W

AU - Rusch, J

AU - Blome, C

N1 - © 2023. The Author(s).

PY - 2023/10

Y1 - 2023/10

N2 - PURPOSE: Adjuvant treatment with immune checkpoint inhibitors like PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT) in high-risk melanoma patients demonstrate a significant improvement in disease-free survival (DFS). Due to specific side effects, the choice of treatment is very often driven by the risk for toxicity. This study addressed for the first time in a multicenter setting the attitudes and preferences of melanoma patients for adjuvant treatment with (c)ICI and TT.METHODS: In this study ("GERMELATOX-A"), 136 low-risk melanoma patients from 11 skin cancer centers were asked to rate side effect scenarios typical for each (c)ICI and TT with mild-to-moderate or severe toxicity and melanoma recurrence leading to cancer death. We asked patients about the reduction in melanoma relapse and the survival increase at 5 years they would require to tolerate defined side-effects.RESULTS: By VAS, patients on average valued melanoma relapse worse than all scenarios of side-effects during treatment with (c)ICI or TT. In case of severe side effects, patients required a 15% higher rate of DFS at 5 years for (c)ICI (80%) compared to TT (65%). For survival, patients required an increase of 5-10% for melanoma survival during (c)ICI (85%/80%) compared to TT (75%).CONCLUSION: Our study demonstrated a pronounced variation of patient preferences for toxicity and outcomes and a clear preference for TT. As adjuvant melanoma treatment with (c)ICI and TT will be increasingly implemented in earlier stages, precise knowledge of the patient perspective can be helpful for decision making.

AB - PURPOSE: Adjuvant treatment with immune checkpoint inhibitors like PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT) in high-risk melanoma patients demonstrate a significant improvement in disease-free survival (DFS). Due to specific side effects, the choice of treatment is very often driven by the risk for toxicity. This study addressed for the first time in a multicenter setting the attitudes and preferences of melanoma patients for adjuvant treatment with (c)ICI and TT.METHODS: In this study ("GERMELATOX-A"), 136 low-risk melanoma patients from 11 skin cancer centers were asked to rate side effect scenarios typical for each (c)ICI and TT with mild-to-moderate or severe toxicity and melanoma recurrence leading to cancer death. We asked patients about the reduction in melanoma relapse and the survival increase at 5 years they would require to tolerate defined side-effects.RESULTS: By VAS, patients on average valued melanoma relapse worse than all scenarios of side-effects during treatment with (c)ICI or TT. In case of severe side effects, patients required a 15% higher rate of DFS at 5 years for (c)ICI (80%) compared to TT (65%). For survival, patients required an increase of 5-10% for melanoma survival during (c)ICI (85%/80%) compared to TT (75%).CONCLUSION: Our study demonstrated a pronounced variation of patient preferences for toxicity and outcomes and a clear preference for TT. As adjuvant melanoma treatment with (c)ICI and TT will be increasingly implemented in earlier stages, precise knowledge of the patient perspective can be helpful for decision making.

KW - Humans

KW - Switzerland/epidemiology

KW - Neoplasm Recurrence, Local/drug therapy

KW - Melanoma/therapy

KW - Skin Neoplasms

KW - Skin

KW - Protein Kinase Inhibitors/therapeutic use

KW - Retrospective Studies

U2 - 10.1007/s00432-023-05027-z

DO - 10.1007/s00432-023-05027-z

M3 - SCORING: Journal article

C2 - 37405475

VL - 149

SP - 11705

EP - 11718

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 13

ER -